N
Naoya Horichi
Researcher at Showa University
Publications - 27
Citations - 502
Naoya Horichi is an academic researcher from Showa University. The author has contributed to research in topics: Lung cancer & Gefitinib. The author has an hindex of 12, co-authored 27 publications receiving 489 citations. Previous affiliations of Naoya Horichi include Vanderbilt University & National Cancer Research Institute.
Papers
More filters
Journal ArticleDOI
Pharmacokinetics of (glycolato-0,0′)-diammine platinum (II), a new platinum derivative, in comparison with cisplatin and carboplatin
Yasutsuna Sasaki,Tomohide Tamura,Kenji Eguchi,Tetsu Shinkai,Yasuhiro Fujiwara,Masaaki Fukuda,Yuichiro Ohe,Masami Bungo,Naoya Horichi,Shigeki Niimi,Koichi Minato,Kazuhiko Nakagawa +11 more
TL;DR: The pharmacokinetics of (glycolato-0,0′)-diammine platinum (II) (254-S; NSC 375101D), one of the new platinum analogues, was examined in a phase I study and showed that the protein-binding abilities of 254-S and carboplatin were almost identical.
Journal ArticleDOI
Patients preferences in chemotherapy for advanced non-small-cell lung cancer.
Takashi Hirose,Naoya Horichi,Tohru Ohmori,Sohjiroh Kusumoto,Tomohide Sugiyama,Takao Shirai,Tetsuji Ozawa,Tsukasa Ohnishi,Mitsuru Adachi +8 more
TL;DR: Patients with lung cancer were significantly more likely than were patients with other respiratory diseases to accept either intensive or less-intensive treatments for a potentially small benefit for "chance of cure, response but not cure," and "symptom relief".
Journal Article
In vitro evaluation of the new anticancer agents KT6149, MX-2, SM5887, menogaril, and liblomycin using cisplatin- or adriamycin-resistant human cancer cell lines.
Yuichiro Ohe,Kazuhiko Nakagawa,Yasuhiro Fujiwara,Yasutsuna Sasaki,Koichi Minato,Masami Bungo,Shigeki Niimi,Naoya Horichi,Masaaki Fukuda,Nagahiro Saijo +9 more
TL;DR: KT6149 was more active than mitomycin C against all lung cancer cell lines and the human myelogenous leukemia cell line and appears to be the best analogue for use in a clinical trial against lung cancer.
Journal ArticleDOI
Phase II study of irinotecan and carboplatin in patients with the refractory or relapsed small cell lung cancer.
Takashi Hirose,Naoya Horichi,Tohru Ohmori,Keiichi Ogura,Takamichi Hosaka,Kohichi Ando,Hiroo Ishida,Hisashi Noguchi,Mitsuru Adachi +8 more
TL;DR: This regimen is effective and well tolerated in patients with relapsed or refractory SCLC, however, the search for even more active regimens should be continued.
Journal ArticleDOI
Enhancement of Sensitivity to Tumor Necrosis Factor α in Non–Small Cell Lung Cancer Cells with Acquired Resistance to Gefitinib
Koichi Ando,Tohru Ohmori,Fumiko Inoue,Tsuyoki Kadofuku,Takamichi Hosaka,Hiroo Ishida,Takao Shirai,Kentaro Okuda,Takashi Hirose,Naoya Horichi,Kazuto Nishio,Nagahiro Saijo,Mitsuru Adachi,Toshio Kuroki +13 more
TL;DR: It is suggested that therapy with TNF-α would be effective in some cases of non-small-cell lung cancer that have acquired resistance to gefitinib.